Select Page
Watch this Webinar to Discover:
- How to funnel your therapeutic through in silico, in vitro, ex vivo, and in vivo model systems in an intelligent way, reducing timelines and maximizing data value
- Use in vitro models to uncover genetic signatures of response and guide in vivo model selection for further validation
- Explore drug mechanism of action using patient-derived xenografts (PDX) enabling clinical-preclinical data corroboration
- Translate preclinical biomarkers into the clinic, and how this enables the identification and stratification of relevant patient populations
Download this Publication to Learn:
- Viability of decreasing secondary mutations by disruption of cell division cycle using eflornithine
- Effect of TMZ on increasing frequency of mutations in U87MG glioblastoma cells while DMFO treated cells showed mutation frequency statistically similar to that of the untreated cells
- DMFO may inhibit progression of DNA mutations caused by alkylating chemotherapy agents such as TMZ
Download this Publication to Learn:
- Advantages to biobanks, pharma and biotech using SNP based assay and barcode deep NGS sequencing, to enable internal quality control for frequent surveillance of mouse and human samples, cell lines, organoids, xenograft models, and patient tissues
- The identity of mouse and human cell lines and models and misidentified cell lines
- Mycoplasma and viral contamination that pose risks for research and lab safety
- Intra- and mouse-human interspecies contamination with 1-2% sensitivity
- Cross-contamination of your mouse and human cell lines and detection of mouse stromal invasion of xenograft tumors
- Annotation of human preclinical and RUO samples with gender and race information
Download this Publication to Learn:
- Methods that can make the design and analysis of MCTs more rational, flexible and powerful
- Methods that make MCTs a better tool in oncology research and drug development
- Statistical framework developed to provide general guidelines on the design, analysis and application of MCTs.
- The advantages of Linear mixed models (LMMs) and frailty models for survival analysis, used in discovering biomarkers and exploring drug mechanisms of action
Download this Quickfact to Understand:
- Comprehensive profile of genes associated with tumor immunity by measuring 1080 mouse transcripts from a single sample
- Immune cell populations and I-O pathways and processes of yours murine immunity pharmacology study samples
- Immunogenomics of murine tumor-immune interactions to elucidate drug mechanism of action and make next decisions in your drug development process
- Drug resistance and development of biomarker signatures of response
Download this Quickfact to Understand:
- Advantages of making data driven decisions using our range of genomics capabilities, next generation sequencing (NGS) services and cutting-edge data analysis platforms
- Genetic features associated with drug response utilizing our historical datasets, and applying our proprietary algorithm for biomarker discovery
- Expansive model datasets, including our large database of NGS-characterized models
- Genes associated with tumor immunity using our Mouse I/O RNA-Seq Panel
Download this Quickfact to Understand:
- High quality pharmacokinetic data generated by in vivo experts to progress your compounds with confidence
- Pharmaceutical and safety properties of your lead candidates
- Method development and validation, quantitation analysis, dosing analysis and biological sample analysis
- Investigation of PD biomarkers for small and large molecules
Download this Quickfact to Understand:
- Two-drug combination effects of synergistic, antagonistic, and additive cell-based assays
- Two common types of drug combination experimental designs: Fixed Ratio: constant concentration ratio and Matrix Ratio: variable concentration ratios
- Dosing data from your existing assays or work with our experts to design a study, taking advantage of CrownBio’s well-validated cell lines and variety of assay options
Watch this video to learn:
- Partnership value in optimizing therapeutic benefits, determining drug mechanism of action and discovering biomarkers
- Experience in conducting pharmacology studies, more than 200 mouse clinical trials, and generating over 10,000 treatment data
- Guidance from our global bioinformatics team who have published bioinformatics solutions in multiple peer-reviewed journals
- CrownBio’s dedicated genomics capabilities, exclusive NGS site and Global Data Center